-Kafila Guest Statement by Association of Students for Equitable Access to Knowledge (ASEAK) Victory for Students and Access to Knowledge in DU Copyright Case: Corporate Publishers Market ends at the gates of the University In a rare and incredible order today, the Delhi High Court has dismissed the copyright infringement case filed by Oxford University Press, Cambridge University Press and Taylor and Francis (Routledge) against Rameshwari Photocopy Shop in Delhi School of Economics...

-The Hindu MSF Secretary General Jerome Oberreit on the increasing threat to affordable health care worldwide. Médecins Sans Frontières (MSF) or Doctors without Borders, the international humanitarian medical aid organisation that is active in 69 countries, serves populations affected by epidemics, armed conflicts, natural calamities and manmade disasters. MSF has relied heavily on generic drugs, much of which has been sourced from India, to deliver health care to some of the most...

-Hindustan Times India’s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc’s patent application was rejected in January 2015. Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further. “By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,” said Henk...

-The Hindu The pursuit of full employment of labour cannot primarily rely on domestic private investment, much less FDI. Only public investment will steady us in the long run. We are increasingly told that the inflow of capital — particularly the foreign direct investment (FDI) variety — increases employment levels and contributes to economic growth. In a rare interview given to The Wall Street Journal in May, Prime Minister Narendra Modi reinforced...

-The Hindu New Delhi: Seed technology major Monsanto says it is suspending plans to introduce an upgraded version of its genetically modified cotton in India because of uncertainty in the “business and regulatory environment”. Activists say this is a “hypocritical” position. On July 6, Monsanto notified the Genetic Engineering Appraisal Committee, the regulatory authority for approval of biotechnology traits in India, that it was withdrawing its application for the commercial release of...